Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia
Monitoring of Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia
This is a prospective observational clinical study to characterise abnormalities of thromboelastography (TEG) parameters in patients with chemotherapy-induced thrombocytopenia. The investigators are also studying the relationship between Multiplate analysis and bleeding in these patients and the effect of platelet transfusions on thrombopoietin level and percent reticulated platelets.
The investigators' hypothesis is that changes in TEG-parameters reflect the patients tendency to bleed.
연구 개요
상세 설명
Thrombocytopenic patients are followed with blood samples (thromboelastography, Multiplate, haematology) daily, Monday to Friday for up to 30 days.
In addition bleeding evaluation is done daily ,using a standardized questionnaire. The questionnaire is filled out after interview of the patient, and som times next of kin and nurses. Nurse journals and medical journals are also used to fill in the questionnaires.
For thromboelastography (TEG) we are looking at which parameters are abnormal, and if there is other factors than platelet count that influence the results. We will also compare TEG from days with and without bleeding, to see if they differ.
For Multiplate we are doing a pilot study to see whether this analysis can be of any use at all in this group of patients. We are looking into which factors that influence the Multiplate result, and if we can see a difference in the results if the patient is bleeding.
For reticulated platelets and thrombopoietin we are studying the levels related to platelet transfusions.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Bergen, 노르웨이, 5021
- Haukeland University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
Patients are eligible for this study if:
They have a haemato-oncologic disease They have, or are expected to have, thrombocytopenia They are expected to need at least one platelet transfusion They are aged 18 years or over They consent to participate
Exclusion Criteria:
Patients are not eligible for this study if:
They have a known congenital clotting disorder They need anticoagulants regularly in the study period They have immune thrombocytopenic purpura
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 시간 관점: 유망한
코호트 및 개입
그룹/코호트 |
|---|
|
Hematooncology patients
No intervention
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
MA
기간: 1 year
|
To characterise changes in the TEG-parameter MA in patients with chemotherapy-induced thrombocytopenia
|
1 year
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Reticulated platelets percent
기간: 1 year
|
To investigate the effect of platelet transfusions on percent reticulated platelets.
|
1 year
|
|
Bleeding
기간: 1 year
|
To investigate the relationship between TEG-parameters, bleeding and need for platelet transfusion. To investigate the influence of HLA antibodies on risk of bleeding and transfusion complications. |
1 year
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Tor A Hervig, dr.med, University of Bergen
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .